

DELAWARE HEART GROUP, P.A.

CHRISTOPHER L. BALDI, D.O., F.A.C.C.
CHRISTOPHER A. BOWENS, M.D., F.A.C.C.
JAMES T. HOPKINS, M.D., F.A.C.C.

B. JOHN HYNES, M.D.
JOSEPH T. WEST, M.D., F.A.C.C.

Medical Arts Pavilion 2
4735 Ogletown-Stanton Road, Suite 2123
Newark, DE 19713
Phone (302) 225-3888
Fax (302) 731-7695

Glasgow Medical Center
2600 Glasgow Avenue, Suite 108
Newark, DE 19702
Phone (302) 834-3700
Fax (302) 834-8330

Middletown Care Center
124 Sleepy Hollow Road, Suite 201
Middletown, Delaware 19709
Phone (302) 449-3150
Fax (302) 449-3160

April 20, 2009

Br 2

U.S. Nuclear Regulatory Commission
Region I, Licensing Assistance Team
475 Allendale Road
King of Prussia, PA 19406

03036153

2009 APR 21 PM 12: 27
RECEIVED
REGION 1

Re: NRC Radioactive Material License No. 07-30784-01

Dear Madam/Sir,

This letter is written to inform you and request your permission prior to transfer of control of the radioactive materials license from Delaware Heart Group, P.A. to Clinical Cardiology Specialists, LLC. The physicians of the Delaware Heart Group are reorganizing; the invasive cardiologists are retaining the name Delaware Heart Group and the non-invasive cardiologists (nuclear medicine cardiologists) are changing their name to Clinical Cardiology Specialists as of June 1, 2009. The existing facilities at 2600 Glasgow Ave, Suite 108, Newark, DE and 124 Sleepy Hollow Road, Suite 201, Middletown, DE) will continue to comply with all regulatory requirements and conditions of the current NRC radioactive material license No. 07-30784-01.

As required by 10 CFR 30.34 and 10 CFR 35.14, we are providing you with information regarding our intentions at the current facilities which are included in our NRC radioactive material license:

- Radioactive materials will continue to be possessed, used and controlled by the licensed facilities;
- All radioactive materials will be properly handled and secured;
- Persons using these materials (authorized users and nuclear medicine technologists) are competent and committed to using radiological controls;
- The authorized users (Christopher A. Bowens, MD and Christopher L. Baldi, DO) involved with our byproduct material and NARM program are currently approved and listed on our current radioactive material license and will remain the authorized users following the business transaction;
- The surveillance program regarding area surveys, wipe tests, and quality control will remain the same following these business transactions. Current equipment and documentation will continue to be used to assure proper radioactive material receipt, use, possession, storage, waste disposal, and accurate patient dosage administration and wipe test quantification.

We acknowledge that the new management will continue to abide by all the constraints, conditions, requirements and commitments of the existing radioactive materials program. We hope that you will contact us shortly to clarify all questions you may have regarding this impending transfer of radioactive material control. Feel free to call us at 302-834-3700. Thank you for your attention in this matter.

Sincerely yours,

Christopher A. Bowens MD

Christopher A. Bowens, MD
Radiation Safety Officer

143670

This is to acknowledge the receipt of your letter/application dated

4/20/2009, and to inform you that the initial processing which includes an administrative review has been performed.

ALCND. 07-30784-01 There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 143670.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.